Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02157896|
Recruitment Status : Completed
First Posted : June 6, 2014
Last Update Posted : August 5, 2016
|Condition or disease|
|Acute Ischemic Stroke|
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||Dynamic Changes of Vascular Endothelial Growth Factor and Endostatin in Association With Circulating Endothelial Progenitor Cells After Acute Ischemic Stroke|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||April 2014|
|Actual Study Completion Date :||May 2014|
Acute ischemic stroke
Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study, and had a score between 6 and 25 on the National Institutes of Health Stroke Scale (NIHSS).
- Modified Rankin Scale scores [ Time Frame: 3 months ]
0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate
- Page 3 of 4 [DRAFT] - disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead.
- Glasgow Outcome Scale scores [ Time Frame: 3 months ]Glasgow Outcome Scale 1 = death; Glasgow Outcome Scale 2 = vegetative state; Glasgow Outcome Scale 3 = severe neurological deficit; Glasgow Outcome Scale 4 = mild neurological deficit and Glasgow Outcome Scale 5 = premorbid level of functioning or completely recovery.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02157896
|Principal Investigator:||Hao Chen, Ph.D.||Shanghai 6th People's Hospital|